EGFR and cancer: Since the activating mutation of EGFR plays a central role in the dysregulation of gefitinib-resistant H1650 NSCLC cells [44], the degradation of EGFR will contribute remarkably to inhibit the proliferation of these EGFR survival dependent cancer cells.